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Abstract
Background:  Exposure to β-Hexachlorocyclohexane (β-HCH), a contaminant of the
hexachlorohexane pesticide lindane, has been implicated as a risk factor in the development of
breast cancers in epidemiological studies. Previous studies in our laboratory have demonstrated
the ability of β-HCH to elicit its actions via a ligand-independent activation of the estrogen receptor
through increased c-Neu (= erbB2 or HER-2) expression and kinase activation in both the BG-1 and
MCF-7 cell lines. In addition, long term exposure (33 passages) to β-HCH was shown to promote
the selection of MCF-7 cells which exhibit a more metastatic phenotype.
Methods: In this current study, we decided to investigate the long-term effects of β-HCH in both
the MCF10AT1 cell line which was derived from a normal epithelial cell line by stably transfecting
a mutated c-Ha-ras and a MMTV-Neu mouse model for mammary cancer in vivo. MCF10AT1 cells
were exposed for 20 passages with β-HCH, 4-OH-Tamoxifen (Tam), or 17-β-estradiol (E2) after
which cells were analyzed for proliferation rates and mRNA expression by RT-PCR. In our in vivo
studies, MMTV-Neu mice were injected with β-HCH and observed for tumor formation over a 70
week period.
Results: β-HCH and Tam selected MCF10AT1 cells demonstrated increased mRNA expression
of MMP-13 (collagenase-3) a marker of increased invasiveness. β-HCH treatment was also seen to
increase the expression in a number of proto-oncogenes (c-Neu, Cyclin D1, p27), cell status
markers (Met-1, CK19), and the inflammatory marker NFκB. Previous studies, have demonstrated
the role of these markers as evidence of malignant transformations, and further illustrate the ability
of β-HCH to be carcinogenic. To demonstrate β-HCH's tumorigenic properties in an in vivo system,
we used an MMTV-Neu mouse model.
MMTV-Neu is a c-Neu overexpressing strain which has been shown to spontaneously develop
mammary tumors at later stages of aging. In this experiment, β-HCH exposure was shown to both
accelerate the appearance (~8 weeks for median tumor-free period) and incidence (~25% increase
at the end of the test period) of tumors when compared to control mice receiving only the corn-
oil vehicle.
Conclusion: Based upon these results, it was concluded that β-HCH does act as a breast cancer
promoter which exerts its tumorigenic activity via increased c-Neu expression.
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Background
It is well known that the etiology of human breast cancer
is significantly affected by environmental factors. One of
those factors frequently discussed as potential cancer pro-
moters is exposure to a class of pollutants known as orga-
nochlorine compounds. These compounds include
chlorinated pesticides such as DDT, hexachlorcyclohex-
ane (HCH), chlordane, and industrial chemicals such as
PCBs and dioxins. Many members of this class of chemi-
cal pollutants have been shown to act as both as estro-
genic compounds and as tyrosine kinase stimulators. β-
Hexachlorocyclohexane (β-HCH), which is the focus on
our current study, is a contaminant of the pesticide γ-hex-
achlorocyclohexane (γ-HCH) or lindane. In previous
studies, β-HCH has been shown to activate c-Neu (also
known as erbB2 or HER2) kinase in breast epithelial cells
[1] and ovarian cancer cells [2]. The high lipophilicity of
β-HCH, together with its extreme persistence (i.e. the esti-
mated half life of 10 years in human tissues) due to its
resistance to metabolism or to other environmental
cleansing forces, makes it extremely persistent and bioac-
cumulating in fatty tissues such as breast tissues. A Finnish
epidemiological study has revealed that the average con-
centration of β-HCH in the breast tissues of cancer
patients is 130 μg/kg fat, compared to 80 μg/kg fat for con-
trols (equivalent of approximately 130 and 80 ppb,
respectively). It must be noted that based on this study,
the difference of a mere 50 ppb could affect the carcino-
genic outcome if we accept their view. The authors of the
study concluded that this organochlorine compound is a
significant risk factor in the development of breast cancers
[3].
While there are still questions regarding the meaning of
such epidemiological correlations or the existence of the
correlation itself, most of the experts would agree that life-
time exposure to strong estrogenic compounds could
increase the risk of developing breast cancer. Such an
opinion is a reasonable one since total lifetime exposure
to estrogens is one of the primary determinants in the
development of this type of hormone sensitive cancer,
and consequently many organochlorine pesticides,
among a host of other xenobiotics, have been shown to
act as estrogenic agents.
Curiously, however, many of the environmental estrogens
identified thus far have been to be mostly weak estrogen
receptor (ER) agonists. Our lead compound, β-HCH, also
belongs to the same type of xenoestrogen which does not
show any binding affinity to ER [4,5] but acts in an estro-
gen mimicking manner though its action to stimulate c-
Neu kinase [1,6]. β-HCH was also found to be a positive
xenoestrogen in a fish (Medaka) assay [7] as well.
In this study, β-HCH has been chosen as a prototype of
this class of environmental pollutants for the purpose of
testing our hypothesis that they act as breast cancer pro-
moters though their action to stimulate c-Neu kinase
activity. This hypothesis has been based on our previous
observation that β-HCH activates tyrosine kinase associ-
ated with c-Neu in vitro in MCF-7 cells [1,6]. However,
whether such an action of β-HCH results in the develop-
ment of highly transformed breast cancer under chronic
exposure conditions both in vitro and in vivo have not
been established yet. The main objectives of this investiga-
tion were: first, to characterize the specific feature of breast
epithelial cells selected and promoted through chronic
exposure to β-HCH and second, to demonstrate that such
exposure to this compound indeed results in the develop-
ment of breast cancer in vivo in an experimental animal
model. Such a mode of promotion is expected to be most
effective in cells with pre-existing genetic risk factors such
as c-Neu overexpression. Because of this fact, we have
selected Ha-ras and c-Neu expressing MCF10AT1 cells in
vitro and MMTV-neu mice for our in vivo model to conduct
our studies in order to gain insights to the basic mecha-
nism of breast cancer promotion through c-Neu kinase
activation.
Methods
Materials
17-β-Estradiol (E2) and 4-OH-Tamoxifen (Tam) were pur-
chased from Sigma Biochemicals (St. Louis, MO). β-hex-
achlorocyclohexane (β-HCH) was purchased from Chem
Service (Westchester, PA). E2 and pesticides were kept as
high concentration stock solutions in ethanol. Human
recombinant EGF other media supplies were obtained
from Gibco BRL (Gaithersburg, MD).
Cell culture
Source and Maintenance
MCF10AT1 cells were obtained from the Michigan Cancer
Foundation and maintained in phenol red free Dulbecco's
modified Eagle's medium with F12 nutrient mixtures
(DMEM/F12; Gibco, BRL) and supplemented with 2.5%
heat-treated equine serum, 20 ng/mL EGF, 100 U/mL pen-
icillin, and 100 μg/mL streptomycin at 37°C under 5%
CO2 conditions.
Selection Process
For each subline, cells were grown in culture media con-
taining either E2 (1 nM); Tam (1 nM), β-HCH (1 μM), or
just the 0.1% ethanol vehicle (control). Media and chem-
icals were refreshed twice a week and the plates were
reseeded when plates reached 80–90 percent confluency
(on average every 10–14 days). For each treatment, three
separate plates were prepared and passaged independ-
ently. Cell passaging was accomplished by trypsinzation
and reseeding of 1 × 106 cells (approximately 2.5% of aBMC Cancer 2007, 7:130 http://www.biomedcentral.com/1471-2407/7/130
Page 3 of 8
(page number not for citation purposes)
near confluent plate) into a 100 mm plate containing the
above media and chemicals. For the quantification of our
long-term studies, each reseeding event constituted one
passage.
Fixation and staining of selected MCF10AT1 cells
In a six-well plate, 1,000,000 cells from the selected sub-
lines were seeded (without selection chemicals). After
reaching confluence (normally 3–4 days), media was
refreshed twice (again without selection chemicals) for an
additional week. Afterwards, cells were fixed by 10% For-
malin (in PBS) for 30 minutes and stained with Giemsa
for 1 minute. After which plates were washed of extra dye
solution with tap water repeatedly. Cells were the
observed under a compound microscope for morphology.
Proliferation test assay
After 20 passages in our test chemicals, cells were reseeded
for cell proliferation assays. Cells were trypsinized from a
starter plate and seeded at a concentration of approxi-
mately 100,000 cells per well in a 12 well plate (Hemocy-
tometer counting) or 10,000 per well in a 96 well plate
(Promega-AQueous one cell proliferation assay). In most
cases, 2 samples from an independent triplicate of a simi-
larly treated selected cell line were chosen (i.e. N = 6). It
must be noted that none of the selection chemicals (i.e.
E2, Tam or β-HCH) were added to the cell culture media
used during this assay. At 24, 48 and 72 hours after plat-
ing, cells were trypsinized (hemocytometer counting) or
analyzed directly for MTS reduction (AQueous assay).
Trypan blue exclusion (0.08% dye) was used to determine
viable cells (normally >96% of total cells).
mRNA analysis of gene expression
Cells that have been selected for 20 passages in our test
chemicals were trypsinized and reseeded (500,000) into
60 mm dishes in our culture media. Note: no additional
selection chemicals (i.e. E2, Tamoxifen, β-HCH) were
added to the media during this analysis. After 24 hours,
the media was refreshed. After an additional 24 hours,
mRNA was extracted from the cells using the Qiagen
(Valencia, CA) RNAeasy kit. cDNA was prepared from the
extracted mRNA using the Omniscript Reverse Tran-
scriptase Kit (Qiagen) and analyzed by real-time PCR on
a Roche lightcycler.
Real-time PCR was performed on a Roche Molecular bio-
chemical "Light Cycler". Samples were prepared using the
Light cycler DNA Master SYBR green I kit. After sample
preparation, cDNA was analyzed with the following
primer pairs:
c-Neu :  5'-AGC TGG TGA CAC AGC TTA-3' FP
[8] 5'-TGG TTG GGA CTC TTG AC-3'
RP
ERα  5' CAA GCC CGC TCA TGA TCA A-3'
FP(228 bp)  5'-CTG ATC ATG GAG GGT CAA ATC
CAC-3' RP
Cyclin D1 5' GGA TGC TGG AGG TCT GCG A-3'
FP(146 bp)  5'-AGA GGC CAC GAA CAT GCA AG-
3' RP
p21  5'-ATT AGC AGC GGA ACA AAG AGT
CAG ACA T-3' FP(318 bp)  5'-CTG TGA AAG ACA
CAG AAC AGT ACA GGG T-3' RP
p27  5'-AAC GTG CGA GTG TCT AAC GG-3'
FP(164 bp)  5'-CTT CCA TGT CTC TGC AGT GC-
3' RP
VEGF  5'-AAG GAG GAG GGC AGA ATC AT-3'
FP(226 bp)  5'-ATC TGC ATG GTG ATG TTG GA-
3' RP
IGF-IR  5'-ACA GAG AAC CCC AAG ACT GAG
G-3' FP(285 bp)  5'-TGA TGT TGT AGG TGT CTG
CGG C-3' RP
c-met  5'-CAG GCA GTG CAG CAT GTA GT-3'
FP(201 bp)  5'-GAT GAT TCC CTC GGT CAG AA-
3' RP
CK19  5'-CTA CAG CCA CTA CTA CAC GAC-
3' FP(148 bp)  5'-CAG AGC CTG TTC CGT CTC
AAA-3' RP
MMP-12  5'-ACA CAT TTC GCC TCT CTG CT-3'
FP(192 bp)  5'-CCT TCA GCC AGA AGA ACC TG-
3' RP
MMP-13  5'-AAC ATC CAA AAA CGC CAG AC-3'
FP(166 bp)  5'-GGA AGT TCT GGC CAA AAT GA-
3' RP
NFκB  5'-CAC TTA TGG ACA ACT ATG AGG
TCT CTG G-3' FP(406 bp)  5'-CTG TCT TGT GGA
CAA CGC AGT GGA ATT TTA GG-3' RP
β-Actin  5'-GGA CTT CGA GCA AGA GAT GG-3'
FP(234 bp)  5'-AGCACT GTG TTG GCT TAC AG-
3' RP
The PCR cycling conditions were 95°C for 15 s, 60°C for
20 seconds and 72°C for 10 seconds
MMTV mice treatments
MMTV-neu mice were obtained from Jackson Laborato-
ries (West Sacramento, CA) and separated into control
and β-HCH treated groups. Each group contained 37–39BMC Cancer 2007, 7:130 http://www.biomedcentral.com/1471-2407/7/130
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virgin female mice. Mice were injected with 33 mg/kg β-
HCH (in corn oil:acetone; 90:10 mixture) or just the vehi-
cle solution at 6, 10, 14 and 18 weeks. Mice were housed
at normal temperature, food, and water conditions and
examined twice weekly for tumor formation in the mam-
mary regions. First palpable tumor time was used to calcu-
late tumor latency in animals.
Statistical Analysis
For proliferation and mRNA expression experiments
Several independently prepared batches of cells for each
treatment group were assessed simultaneously to obtain
means and standard deviations among different batches
(i.e. "N" values shown in figure captions). ANOVA and
Fisher's least-significant differences test (SYSTAT 11 Com-
puter Software) were used to determine the significance of
difference between control and chemically treated groups.
A probability value of less than 0.05 was regarded as sig-
nificant. Error bars in the figures indicate standard devia-
tions from the mean.
For MMTV mouse tumor studies
The tumor free interval for mice in the β-HCH and corn-
oil only treat groups were compared using the Cox pro-
portional hazard model and the log rank test for compar-
ison of significance between survival curves (MedCalc
computer software).
Results
Observations on phenotypic changes in MCF10AT1 cells 
exposed to chemicals for 20 passages
Cellular morphology in a confluent system
After exposure for 20 passages with our test chemicals,
cells were plated and grown to confluence in six-well
plates. After cells reached confluence, media was refreshed
twice for an additional week. Cells were then fixed,
stained with Giemsa and observed under a microscope
(Figure 1). There were no observable differences between
independent, yet similarly treated sublines. In regards to
comparisons between sublines receiving different chemi-
cal treatments, both the control and E2  selected
MCF10AT1 cells (Fig 1A and 1B, respectively) exhibit sim-
ilar morphology with relatively consistent cellular densi-
ties and a lack of secondary formations. E2 selected cells,
however, did show a more densely packed "cobblestones"
appearance with the presence of islands consisting of well
packed larger cells. Tam selected MCF10AT1 cells (Fig
1C), exhibited spindle shaped cells with clear foci forma-
tion indicating additional cellular transformation of the
MCF10AT1 cell line consistent with the loss of contact
inhibition, allowing the cell's ability for growth beyond
confluency. On the other hand, β-HCH selected
MCF10AT1 cells (Fig 1D) showed two types of mixtures of
cells without distinct forming foci. One type of cells
formed large areas of stationary cobblestone assemblies
similar to E2 treated cells showing a degree of varying cell
sizes of cell densities with large nucleies. The second type
of cells showed well dispersed (i.e. less well packed than
the first type), spindle shaped cells which did not form
either foci or islands of packed assemblies of cells. This
observation indicates that while β-HCH exposure also
appears to promote and select specific phenotypes in the
MCF10AT1 cell line, its actions are disparate from that
which occurs in Tam treated cells since there is no visible
foci formation.
Changes in baseline cellular proliferation
After exposure for 20 passages with our test chemicals,
cells were reseeded and grown in culture media without
the influence of selection chemicals. Cells were then
quantitated via hemocytometer counting (Fig 2A) or MTS
reduction (Fig. 2B). MTS reduction to its formazen prod-
uct, has been established as a directly proportional to
amount of living cells [9]. At 24 hours, there was, in gen-
eral, no significant differences in cell number amount the
cell groups indicating similar plating efficiencies. Over the
next two successive 24 periods, all chemically selected
subgroups of long-term selected lines demonstrated
increased cell proliferation when compared to the control
group. In particular, Tam and β-HCH treated cell lines had
nearly double the increase in cells over successive 24 hour
periods when compared to the control group. Interest-
ingly, the difference between the two assay methods with
Giemsa stained MCF10AT1 sublines (Control, E2, 4-OH- Tamoxifen and β-HCH selected) grown for one week after  reaching confluency Figure 1
Giemsa stained MCF10AT1 sublines (Control, E2, 4-OH-
Tamoxifen and β-HCH selected) grown for one week after 
reaching confluency.BMC Cancer 2007, 7:130 http://www.biomedcentral.com/1471-2407/7/130
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regards to proliferation (i.e. C < E2 = β-HCH < Tam for 2A
but C < E2 = Tam < β-HCH for 2B) may be related to an
observation during hemocytometer analysis. It was noted
that β-HCH and E2 cells appeared to be slightly larger than
both the Tam and control vehicle treated cells which may
account for the more proportional increase in MTS reduc-
tion activity.
Changes in mRNA expression (Table 1)
After exposure for 20 passages with our test chemicals,
cells were reseeded and grown in standard culture media
without the influence of selection chemicals. The mRNA
from these cells were then extracted and quantitated for
expression using real-time RT-PCR. Expression of various
genes were normalized with respects to β-actin for each
sample. These normalized values were then expressed in
Table 1 relative to the expression of the same marker in
the control group. Molecular profiles were constructed
based on the selected cell line's ability to express various
markers of transformation (c-Neu, cyclinD1, p21,
p27(waf)), cell status (VEGF, IGF-R, c-Met, CK19), inva-
siveness (MMPs -12 and -13) and inflammation (NFκB).
In general, all sublines exhibited increase markers of
transformation. Curiously, both cell status and inflamma-
tory markers were upregulated in β-HCH treated cell lines,
down-regulated in the Tam treated cell lines and demon-
strated mixed results in E2 selected cell lines. Among the
expression of the invasive MMP markers, MMP-13 was
very high in both Tam and β-HCH selected cells and
MMP-12 was elevated only in β-HCH selected cells. These
results indicate that while all three of our chemicals were
able to promote specific phenotypes in the MCF10AT1
Measurement of cell proliferation in MCF10AT1 sublines (Control, E2, Tam and β-HCH selected) as determined by (A) cell  counts or (B) MTS bioreduction at 24, 48 and 72 hours after initial cell plating Figure 2
Measurement of cell proliferation in MCF10AT1 sublines (Control, E2, Tam and β-HCH selected) as determined by (A) cell 
counts or (B) MTS bioreduction at 24, 48 and 72 hours after initial cell plating. N = 5–6 for both experiments *p < 0.05, ** p < 
0.01 versus control.BMC Cancer 2007, 7:130 http://www.biomedcentral.com/1471-2407/7/130
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cells lines, each of the selected lines show distinct charac-
teristics, implying that the nature of these transformations
may be occurring via differing mechanisms.
In vivo exposure of β-HCH in MMTV-neu mice
Tumor Formation
Previous in vitro cellular studies in our laboratory using
MCF-7 cells [10] characterized those selected through 33
passages of exposure to β-HCH be ER positive, c-Neu
over-expressed, rapidly proliferative and invasive. Previ-
ous studies from our laboratory have consistently shown
that the acute primary action of β-HCH in MCF-7 cells is
rapid activation of c-Neu tyrosine kinase [1,6,11]. Accord-
ingly we have formulated a hypothesis that persistent c-
Neu kinase activation for long time periods lead to pro-
motion of malignant phenotype of affected cells. To test
this hypothesis in vivo we decided to utilize a MMTV-Neu
mouse model for mammary cancer, according to the pro-
tocol of Yu et al. [12]. This transgenic strain is an ideal
model for our studies due to its overepression of the c-
Neu receptor and its innate ability to spontaneously form
mammary tumors. Six-week old virgin female mice were
injected with β-HCH (33 mg/kg) or the corn oil vehicle.
Injections were repeated 3 additional times on a monthly
basis. Mice were inspected weekly for tumor formation by
palpations and a Kaplan-Meier survival curve on tumor
occurrence or lack thereof was constructed. (Figure 3). The
results showed that β-HCH exposure accelerates the
appearance of breast tumors in these mice to the extent
that the median survival time point of tumor formation in
50% of the population was eight weeks earlier in the β-
HCH treated group than control (40 weeks vs 48 weeks).
Furthermore, β-HCH treatment caused 100% tumorgene-
sis while vehicle treated control groups showed only 75%
tumorgenesis even at the end of 70 weeks test period.
Discussion
While previous studies in MCF-7 cells have established
that long-term exposure to β-HCH, Tam [10] and E2
resulted in increases in metastatic potential via increased
invasiveness and expression of metastatic markers, we did
not get the overall perspectives of how applicable that
finding is to other types of breast cancer cells or how
unique is β-HCH in comparison to other cancer promot-
ers in causing this type of transformation. Based on back-
ground information obtained from these previous
studies, we decided to compare the ability of all three of
these compounds to promote changes in the metastatic
potential in the epithelial MCF10AT1 cell line. The
MCF10AT1 cell line was chosen based on its known back-
ground of Ha-ras mutation as the genetic risk factor intro-
duced to the non-transformed MCF10A line, and its
ability to be transformed into a variety of a carcinomas
when they were xenographed into the breast fat pad of
nude mice [13,14] as well as its well defined expression of
both the estrogen and c-Neu receptors. When this cell line
was subjected to β-HCH, E2, or Tam exposure for 20 pas-
sages, we could clearly recognize that they all express
more transformed phenotypes judging by the changes in
their cellular morphology, and proliferation rates. The
wide difference among those selected sublines in terms of
their cell morphological shape and density of the trans-
formed MCF10AT1 cells indicated that there may be other
fundamental differences among them. This led us to
Table 1: Molecular Profiles of MCF10AT1 sublines (Control, E2, Tam and β-HCH selected). The markers shown based on mRNA 
expression of genes determined though quantitative RT-PCR. Values represent fold-increase of a marker's expression versus β-actin of 
a selected subline when compared to control (ethanol vehicle). N = 5–6 for each experiment * p < 0.05 and **p < 0.01 vs. treatment 
versus control.
MCF10AT1 sublines selected for 20 passages in DMEM/F12 media containing:
Control E2 (1 nM) Tam (1 nM) β-HCH (1 uM)
Proto-oncogenes
cNeu 1.00 1.64* 1.79* 2.73**
Cyclin D1 1.00 1.84* 1.88* 2.50**
p21 1.00 2.05* 1.07 1.19
p27 1.00 2.02* 1.73* 2.80*
Cell Status
VEGF 1.00 3.12* 0.72 1.34
IGF-IR 1.00 1.99* 2.79* 3.77**
c-met 1.00 2.06** 0.66* 1.26
CK19 1.00 0.78* 0.72* 1.67*
Invasive
MMP-12 1.00 0.85 0.41* 3.50*
MMP-13 1.00 0.86 18.51** 14.12**
Inflammation
NFkB 1.00 3.20** 0.24* 2.59**BMC Cancer 2007, 7:130 http://www.biomedcentral.com/1471-2407/7/130
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examine their molecular profiles. When we examined
their molecular profiles through the use of a quantitative
RT-PCR approach, it became also apparent that there are
distinct differences among all 3 selected lines and control
(Table 1) although all 3 selected cell lines showed some
common markers of transformation such as elevated
mRNA expression of cyclinD1, and p27 (kip) genes. For
instance, the increase in mRNA for c-Neu gene was more
significant upregulated in β-HCH group when compared
to the Tam and E2 treated group. Interestingly, significant
up-regulation of VEGF and p21(waf) mRNA expression
could be observed only in E2 selected line. These observa-
tions indicated that there are clear signs of differences in
the patterns of mRNA expressions among all three
selected sublines. With respect to the markers for the
transformed cell status, VEGF induction was highest in E2-
selected line, but that of CK19 (cytokeratin) was most sig-
nificant in β-HCH-selected ones. In contrast, the Tam
selected line showed reduced expressions in all status
markers. A significant finding on the markers of invasive-
ness is that for MMP-13 (collegenase 3) of which mRNA
expressions were tremendously upregulated from control
(selected with the vehicle only) in both β-HCH and Tam
selected lines but not at all in E2 selected one. Since MMP-
13 (collagenase-3) expression is a well-accepted marker of
malignancy of mammary epithelial cells [15], we have
decided that in future studies we should rely on this
mRNA expression as one of the markers in judging the
extent of malignant transformation. By contrast, up-regu-
lation of NF-κB, a marker of inflammation was up-regu-
lated in E2 and  β-HCH selected cells but not in Tam
selected ones. Another characteristic seen only in β-HCH
selected cells is the increased mRNA expression of IRS-1,
insulin receptor substrate protein. Interim conclusions we
have derived from this set of profiling tests are: (a) both β-
HCH cells demonstrated the most significant elevated c-
Neu mRNA expression, (b) judging by those invasiveness
markers, particularly MMP-13, β-HCH and tamoxifen
selected cells are more transformed and (c) both β-HCH
and E2 selected cells show the sign of inflammation, while
Tam selected line is definitely does not. One key observa-
tion is that despite these signs of significant transforma-
tion of β-HCH selected cells, they still maintain high
levels of expression of cytokeratin (CK19), which is a
marker of differentiated non-transformed mammary epi-
thelial cells.
The differing molecular profiles in the RT-PCR results
illustrate that while all cells appear to be transformed
(with respect to protoncogene upregulation), albeit at var-
ying degrees, there are possible common mechanism in
which may lead to similar phenotypical changes. For
example, proliferation rates appear to be related to
increased invasiveness which where seen in both the Tam
and β-HCH selected cells but to a lesser extent in the E2
selected cells. In the case of E2 and β-HCH selected sub-
lines, the increase in their proliferative activities do not
appear to correlate with foci-like formation. Yet, these two
sublines do show increased expression of inflammatory
marker, NFκB, which is accompanied with up-regulation
of VEGF. It has been shown that activation of NFκB is pos-
itively linked to a subset of estrogen receptor-positive
human breast cancer, which represents clinically aggres-
sive ER-positive breast cancer. Thus, while much more
work would be needed to firmly establish the exact molec-
ular phenotype of β-HCH selected cells, the current study
results have established that β-HCH is a definite tumor
promoter in vivo, and that the molecular profile of β-HCH
selected cells is distinct as compared to those MCF10AT1
cells selected by E2 or Tam.
While there has been a number of ecotoxicological and
epidemiological studies linking organochlorine exposure
to increased incidences of breast cancers, this study is the
first one to demonstrate the direct effect of organochlo-
rine exposure to increased tumor formation in an in vivo
system (Figure 3). It must be emphasized that the selec-
tion of this MMTV-neu model was based on the special
characteristics of β-HCH exposed epithelial cells to show
high mRNA expression activities of c-Neu and its kinase.
We reasoned that in mice already constitutively expressing
c-Neu, which is particularly selectively concentrated in
mammary tissues, the action of β-HCH would likely be
Kaplan-Meier plot of tumor formation in c-Neu MMTV mice  injected with β-HCH (solid line) or corn-oil vehicle (dashed  line) Figure 3
Kaplan-Meier plot of tumor formation in c-Neu MMTV mice 
injected with β-HCH (solid line) or corn-oil vehicle (dashed 
line). P = 0.0004 for significance between curves as deter-
mined by a comparison of survival curves (log rank test). N = 
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manifested clearly. Results illustrating the ability of β-
HCH to promote earlier onset time and to increase the
percentage of tumorgenicity in MMTV-neu mice indicate
that this organochlorine is a powerful cancer promoter in
vivo. The β-HCH treated mice had an onset time of nearly
three months earlier than corn-oil treated mice for 25%
tumor incidence (32 weeks vs 44 weeks). In addition,
nearly a quarter of control treated MMTV-neu mice did
not have any tumor formation even after 70 weeks. This
set of data illustrates that c-Neu overexpression in mam-
mary epithelial cells is a definite risk factor, and that β-
HCH is a definite tumor promoting agent in vivo, at least
in this mouse breast cancer model.
Conclusion
Based on our results which indicate that β-HCH exposure
increases the metastatic characteristics in the MCF10AT1
cell model and tumor formation in the MMTV-neu mouse
model, we conclude that β-HCH can act as a breast cancer
promoter via its ability to promote c-Neu overexpression.
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